Anfield Capital Management, LLC Uni Qure N.V. Transaction History

Anfield Capital Management, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 09, 2022	BUY	$16.98 - $25.54 $696 - $1,047	41 Added 5.77%	751 $14,000
Q2 2022 Aug 09, 2022	BUY	$13.15 - $20.45 $2,156 - $3,353	164 Added 30.04%	710 $13,000
Q1 2022 May 13, 2022	BUY	$14.54 - $21.5 $4,143 - $6,127	285 Added 109.2%	546 $10,000
Q4 2021 Feb 03, 2022	BUY	$20.24 - $36.01 $4,918 - $8,750	243 Added 1350.0%	261 $5,000
Q3 2021 Nov 04, 2021	BUY	$26.01 - $38.22 $468 - $687	18 New	18 $1,000

142

35.3M

1.54M

389K

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $300M
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

Get notified when there are updates to the investment portfolio of Anfield Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Anfield Capital Management, LLC with notifications on news.